The terms, per the grant. On January 21, 2020, Sanofi was issued US10538567B2, "Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists." The CPC tags — C07K 14/57563 and C07K 14/605 (the glucagon/GLP-1 peptide families), plus A61K 38/2278 — place it squarely in the engineered-incretin-peptide stack that now anchors the most valuable franchise in therapeutics.
Why a business desk flags a 2020 grant in 2026: the multi-receptor peptide — a single molecule agonizing GLP-1, glucagon, and GIP receptors — is the structural idea behind the tri-agonist programs now commanding premium valuations and licensing interest. The point is not that this specific molecule won; the point is that the date stamp shows the thesis was real and protected before the market priced it.
The disciplined read for a model: issued composition-of-matter peptide claims are the bankable assets in metabolic drugs, not the platform narrative. A grant on a peptide family is the kind of asset that underwrites an upfront payment, a milestone schedule, or a defense against an early follow-on. Naming the grant by number is how you separate a real estate from a press-release pipeline.
What the document does not say: it does not promise clinical superiority over a dual agonist, it does not clear freedom to operate around competing peptide estates, and it does not guarantee the molecule reaches a label. Those are separate facts in separate records — a grant is an exclusivity claim on a structure, not a verdict on the medicine.
The takeaway for anyone valuing the GLP-1 lane: count the issued peptide grants by priority date and read what each independent claim actually recites. Sanofi's tri-agonist grant is a concrete, dated brick from early 2020 — evidence that the arms race over multi-receptor metabolic peptides was being fought in the patent office well before it reached the earnings calls.